PROVECTUS’ INTRALESIONAL PV-10 CLINICAL DATA TO BE PRESENTED TO THE 2014 INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH

Print E-mail
Thursday, 16 October 2014 18:07
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
Read more...
 

RELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS

Print E-mail
Thursday, 16 October 2014 18:04

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014.

Read more...
 

INC RESEARCH SIGNS AGREEMENT TO PERFORM FDA DUE DILIGENCE AUDIT OF REGULATORY DOCUMENTS FOR PROVECTUS BIOPHARMACEUTICALS

Print E-mail
Tuesday, 14 October 2014 13:57

KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

Read more...
 

Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims

Print E-mail
Tuesday, 07 October 2014 10:23
Read more...
 

Healthcare Valuation Experts Tackle Advanced Concepts

Print E-mail
Monday, 06 October 2014 16:06
Healthcare valuation and consulting experts seeking help in navigating the treacherous regulatory landscape of healthcare can’t afford to miss an in-depth symposium this December presented by the National Association of Certified Valuators and Analysts™ (NACVA®) and the Consultants’ Training Institute™ (CTI™).  The Advanced Healthcare Valuation and Consulting Symposium will be held December 12–13, 2014, in San Diego, CA at the Solamar Hotel.
Read more...
 

CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial

Print E-mail
Friday, 03 October 2014 13:27

Vienna, VA-- CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).

Read more...
 

Clinical Decision Support Tools Can Help Doctors Quickly and Accurately Diagnose Ebola and other Infectious Diseases

Print E-mail
Friday, 03 October 2014 09:03

ROCHESTER, NY--Four years ago, the Institute of Medicine recommended the Department of Health and Human Services promote the use of clinical decision support tools to ensure doctors quickly and accurately detect and diagnose bioterrorism and infectious disease outbreaks.

Read more...
 

Marijuana Use Associated with Lower Death Rates In Patients with Traumatic Brain Injuries

Print E-mail
Thursday, 02 October 2014 12:33

 

LOS ANGELES - Surveying patients with traumatic brain injuries, a group of Los Angeles Biomedical Research Institute (LA BioMed) researchers reported today that they found those who tested positive for THC, the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.

Read more...
 

Protea Biosciences and InSphero AG successful in Mass Spectrometry Imaging of 3D microtissues

Print E-mail
Thursday, 02 October 2014 11:31
Read more...
 

CEL-SCI & U.S. NAVY ADMINISTER MULTIKINE TO FIRST VOLUNTEER PATIENT IN PHASE I CLINICAL TRIAL FOR TREATMENT OF ANAL WARTS IN HIV/HPV CO-INFECTED PATIENTS

Print E-mail
Monday, 29 September 2014 12:11

Vienna, VA, September 29, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD).

Read more...
 
<< Start < Prev 1 > >>

Page 1 of 2

Newsletter

BioMedReports Active Stocks: Advaxis, DexCom, Cytokinetics, Valeant Pharmaceuticals, New Link Genetics: U.S. stocks moved mo... http://t.co/Zhnt4Dj44W
2hreplyretweetfavorite
BioMedReports Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential... http://t.co/p5To7JFYL2
10hreplyretweetfavorite
BioMedReports Active Stocks: Tetraphase Pharmaceuticals, Repros Therapeutics, Horizon Pharma, Theravance Inc, Myriad Genetic... http://t.co/smkGY1yTQM
navigation
Benzinga.com supporter Seeking Alpha Certified